前蛋白转化酶枯草溶菌素-kexin 9型抑制剂对血管内皮的保护作用机制研究进展  

Research progress on the protective mechanism of proprotein convertase subtilisin/kexin type 9 inhibitors on vascular endothelium

作　　者：冯艳 罗文平[2] 张明明 佘林聪 王家欣 孙涌鑫 陈昊青 张薇 FENG Yan;LUO Wengping;ZHANG Mingming;SHE Lincong;WANG Jiaxin;SUN Yongxin;CHEN Haoqing;ZHANG Wei(Department of Cardiovascular Medicine,the Second Affiliated Hospital of Air Force Medical University,Xi′an,Shaanxi,710038;Shaanxi University of Traditional Chinese Medicine,Xianyang,Shaanxi,712046)

机构地区：[1]空军军医大学第二附属医院心血管内科,陕西西安710038 [2]陕西中医药大学,陕西咸阳712046

出　　处：《实用临床医药杂志》2024年第15期142-148,共7页Journal of Clinical Medicine in Practice

基　　金：国家自然科学基金面上项目(82270366)。

摘　　要：前蛋白转化酶枯草溶菌素-kexin9型抑制剂(PCSK9抑制剂)不仅具有良好的降脂作用,还具有改善心血管结局、减轻氧化应激及改善血管内皮等多效性作用。近年来,PCSK9抑制剂的不断研发为心血管疾病治疗提供了新思路,本文就PCSK9抑制剂的多效性作用机制研究,尤其是对于血管内皮功能的作用机制研究予以综述。Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors not only have good lipid-lowering effects,but also have pleiotropic effects such as improving cardiovascular outcomes,relieving anti-inflammation,relieving oxidative stress and improving vascular endothelium.In recent years,the continuous development of PCSK9 inhibitors provides new ideas for the treatment of cardiovascular diseases.This article reviewed the pleiotropic mechanisms of PCSK9 inhibitors,especially on vascular endothelial function.

关 键 词：前蛋白转化酶枯草溶菌素-kexin9型抑制剂 血管内皮 多效性 血脂 心血管结局 炎症 氧化应激 自噬 

分 类 号：R544[医药卫生—心血管疾病] R543[医药卫生—内科学] R34[医药卫生—临床医学]